Program
CagriSema A
In Novo Nordisk’s own words, CagriSema is a fixed-dose combination of a long-acting amylin analog, cagrilintide and a GLP-1 receptor agonist, semaglutide.
. Its studies are mostly in Obesity, led by Novo Nordisk.
Furthest: phase 1, since Nov 29, 20241 company-led study, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novo Nordisk | 10 open or running | phase 1since Nov 29, 2024 | Nov 29, 2024 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 29, 2024First study: phase 1 study in ObesityFirst studyNCT06716307 · 18 enrolled · United States
TargetBeta
“CagriSema is a fixed-dose combination of a long-acting amylin analog, cagrilintide and a GLP-1 receptor agonist, semaglutide.”company, read by Claude · source
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| zenagamtide | Novo Nordisk | phase 3 | 35 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06716307Obesity · United States | 1 | Completed | Mar 28, 2025 | 18 |
How it is read
Names in the registry
- “CagriSema A”, 1 entry
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.